<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00154102</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 62202-013</org_study_id>
    <nct_id>NCT00154102</nct_id>
  </id_info>
  <brief_title>Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)</brief_title>
  <acronym>CRYSTAL</acronym>
  <official_title>Open, Randomized, Controlled, Multicenter Phase III Study Comparing 5FU/ FA Plus Irinotecan Plus Cetuximab Versus 5FU/FA Plus Irinotecan as First-line Treatment for Epidermal Growth Factor Receptor-expressing Metastatic Colorectal Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck KGaA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck KGaA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Drugs used against cancer work in different ways to stop the growth of tumor cells, either by
      killing the cells or by stopping them from dividing. Monoclonal antibodies, such as
      cetuximab, can block tumor growth in different ways. Giving combination chemotherapy together
      with cetuximab as first treatment after diagnosis of a metastatic colorectal cancer
      ('1st-line' treatment) may improve the treatment efficacy. However, it is not yet known
      whether giving combination chemotherapy together with cetuximab is more effective than
      combination chemotherapy alone. This open-label trial investigates the effectiveness of
      cetuximab in combination with a standard and effective chemotherapy (5-Fluorouracil
      (5FU)/Folinic acid (FA) plus irinotecan) for metastatic colorectal cancer in first-line
      setting, compared to the same chemotherapy alone on patient expressing the epidermal growth
      factor (EGF) receptor.

      Patients expressing this EGF Receptor will be randomly assign in one of the 2 groups to
      either receive the combination chemotherapy alone or with cetuximab (open-label study) and
      will then be treated until progression of the disease or unacceptable toxicity occur. Regular
      efficacy assessments (every 8 weeks) based on imaging will be performed throughout the study
      together with regular safety assessments (e.g. safety labs). An independent Safety Board of
      experts will also monitor safety data.

      After participant discontinuation from the trial, regular updates on further treatments and
      survival status will be requested from the investigator.

      The entire study (from the first patient entering the study to the last collect of follow-up
      information) is 4-5 years long.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2004</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">December 2006</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time (OS)</measure>
    <time_frame>Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
    <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time (KRAS Wild-Type Population)</measure>
    <time_frame>Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
    <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival Time (KRAS Mutant Population)</measure>
    <time_frame>Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
    <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response - Independent Review Committee (IRC) Assessments</measure>
    <time_frame>Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).
Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Participants With No Residual Tumor After Metastatic Surgery</measure>
    <time_frame>time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007</time_frame>
    <description>Participants with no residual tumor after on-study surgery for metastases</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status</measure>
    <time_frame>at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Assessment (EORTC QLQ-C30) Social Functioning</measure>
    <time_frame>at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
    <description>Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety - Number of Patients Experiencing Any Adverse Event</measure>
    <time_frame>time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007</time_frame>
    <description>Please refer to Adverse Events section for further details</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1221</enrollment>
  <condition>Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>Cetuximab Plus FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>FOLFIRI Alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Number of Cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>Cetuximab Plus FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)</intervention_name>
    <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
    <arm_group_label>Cetuximab Plus FOLFIRI</arm_group_label>
    <arm_group_label>FOLFIRI Alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of histologically confirmed adenocarcinoma of the colon or rectum

          -  Inoperable metastatic disease

          -  Immunohistochemical evidence of epidermal growth factor receptor expression in tumor
             tissue

          -  Presence of at least 1 bi-dimensionally measurable index lesion

        Exclusion Criteria:

          -  Previous irinotecan-based chemotherapy

          -  Previous chemotherapy for colorectal cancer except adjuvant treatment if terminated
             more than 6 months before the start of study treatment

          -  Radiotherapy, surgery (excluding prior diagnostic biopsy) or any investigational drug
             in the 30 days before the start of study treatment

          -  Brain metastasis
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric van Cutsem, Professor</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Gasthuisberg, Department Internal Medicine, Leuven, Belgium</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Buenos Aires</city>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bedford Park</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nedlands</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>West Perth</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodville</city>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Innsbruck</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Klagenfurt</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kufstein</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salzburg</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Pölten</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Veit an der Glan</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wels</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wien</city>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Antwerpen</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bonheiden</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bruxelles</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edegem</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gent</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liège</city>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Goiania</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Porto Alegre</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santo André</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sao Paulo</city>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pleven</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Plovidiv</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sofia</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varna</city>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago-Las Condes</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santiago-Providencia</city>
        <country>Chile</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chomutov</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Turku</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colmar</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Roche sur Yon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lorient</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Sites</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perigueux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rennes Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Gregoire</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strasbourg</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toulon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Villejuif Cedex</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dortmund</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dresden</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt am Main</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Freiburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göttingen</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Halle</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Homburg/Saar</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mainz</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>München</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oldenburg</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Alexandroupolis</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heraklion</city>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pokfulam</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Shatin</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Debrecen</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Györ</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kecskemét</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ancona</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Aviano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Benevento</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Firenze</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mantova</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Modena</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Reggio Emilia</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rozzano</city>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mexico</city>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Apeldoom</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blaricum</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Den Haag</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Roosendaal</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zwolle</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bialystok</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gliwice</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krakow</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Opole</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznan</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warsaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wroclaw</city>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cluj Napoca</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Iasi</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suceava</city>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Banska Bystrica</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bratislava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kosice</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trnava</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zilina</city>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cape Town</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Durban</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johannesburg</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Elizabeth</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pretoria</city>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>A Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cadiz</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Changhua</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chiayi</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charkassy</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Donetsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kiev</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Krivoy Rog</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lugansk</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lviv</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Uzhgorod</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zhaporozhye</city>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brighton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cambridge</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Guildford</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kent</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leicester</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Peterborough</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rhyl</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sutton</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Bulgaria</country>
    <country>Chile</country>
    <country>Czech Republic</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hong Kong</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Singapore</country>
    <country>Slovakia</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <removed_countries>
    <country>Estonia</country>
    <country>Israel</country>
  </removed_countries>
  <results_reference>
    <citation>Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009 Apr 2;360(14):1408-17. doi: 10.1056/NEJMoa0805019.</citation>
    <PMID>19339720</PMID>
  </results_reference>
  <results_reference>
    <citation>Van Cutsem E, Lang I, Folprecht G, Nowacki M, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Celik I, Kohne C Cetuximab plus FOLFIRI in the treatment of metastatic colorectal cancer (mCRC): The influence of KRAS and BRAF biomarkers on outcome: Updated data from the CRYSTAL trial. ASCO 2010 Gastrointestinal Cancers Symposium, Orlando, USA January 2010 Abstract No: 281</citation>
  </results_reference>
  <results_reference>
    <citation>Lang I, Kohne CH, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Zubel A, Van Cutsem E Cetuximab plus FOLFIRI in 1st-line treatment of metastatic colorectal cancer: Quality of life (QoL) analysis of patients (pts) with KRAS wild-type (wt) tumours in the CRYSTAL trial. European Journal of Cancer Supplements. 2009 7(2):345</citation>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 8, 2005</study_first_submitted>
  <study_first_submitted_qc>September 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 12, 2005</study_first_posted>
  <results_first_submitted>November 30, 2010</results_first_submitted>
  <results_first_submitted_qc>January 27, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 23, 2011</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 30, 2017</last_update_posted>
  <responsible_party>
    <name_title>Monika Foerster</name_title>
    <organization>Merck Serono</organization>
  </responsible_party>
  <keyword>Metastatic colorectal cancer</keyword>
  <keyword>EGFR</keyword>
  <keyword>Irinotecan</keyword>
  <keyword>cetuximab</keyword>
  <keyword>first-line treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irinotecan</mesh_term>
    <mesh_term>Camptothecin</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
    <mesh_term>Folic Acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First/Last subject in: 10 Aug 2004/4 Nov 2005. Clinical cut-off efficacy analyses except survival: 27 Jul 2006, Cut off date IRC data: 14 Dec 2006; cut-off safety analyses: 30 Nov 2007; cut-off survival analyses: 31 May 2009; cut-off KRAS analyses: 28 Aug 2009.
1221 subjects were randomised or treated, of whom 1198 were randomised and treated.</recruitment_details>
      <pre_assignment_details>At the prescreening visit the subject completed the first informed consent form, and a sample of tumor tissue for determination of EGFR expression was to be obtained.
The screening (baseline) visit was performed no more than 21 days before randomization. EGFR-expressing subjects completed a second informed consent form to participate in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cetuximab Plus FOLFIRI</title>
          <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
        </group>
        <group group_id="P2">
          <title>FOLFIRI Alone</title>
          <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="599">Randomized and treated subjects; 1 additional subject was treated but not randomised</participants>
                <participants group_id="P2" count="599">Randomized and treated subjects; 3 additional subjects were treated but not randomised</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="592"/>
                <participants group_id="P2" count="597"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>investigational study phase ongoing</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cetuximab Plus FOLFIRI</title>
          <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
        </group>
        <group group_id="B2">
          <title>FOLFIRI Alone</title>
          <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="599"/>
            <count group_id="B2" value="599"/>
            <count group_id="B3" value="1198"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <description>Age missing for 1 subject</description>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="60.0" spread="10.52"/>
                    <measurement group_id="B2" value="59.8" spread="11.06"/>
                    <measurement group_id="B3" value="59.9" spread="10.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age, Customized</title>
          <description>Age missing for 1 subject</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="374"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="751"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="224"/>
                    <measurement group_id="B2" value="222"/>
                    <measurement group_id="B3" value="446"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="230"/>
                    <measurement group_id="B2" value="243"/>
                    <measurement group_id="B3" value="473"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="369"/>
                    <measurement group_id="B2" value="356"/>
                    <measurement group_id="B3" value="725"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Western Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="262"/>
                    <measurement group_id="B2" value="267"/>
                    <measurement group_id="B3" value="529"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Eastern Europe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="201"/>
                    <measurement group_id="B3" value="404"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rest of the World</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="134"/>
                    <measurement group_id="B2" value="131"/>
                    <measurement group_id="B3" value="265"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments</title>
        <description>Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
        <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>Primary analysis on Intent to Treat (ITT) population i.e. all randomized subjects who have received at least one dose of randomized treatment (allocation to treatment groups as randomized).</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival (PFS) Time - Independent Review Committee (IRC) Assessments</title>
          <description>Duration from randomization until radiological progression (based on modified World Health Organisation (WHO) criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
          <population>Primary analysis on Intent to Treat (ITT) population i.e. all randomized subjects who have received at least one dose of randomized treatment (allocation to treatment groups as randomized).</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.9" lower_limit="8.0" upper_limit="9.4"/>
                    <measurement group_id="O2" value="8.0" lower_limit="7.6" upper_limit="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was planned with 633 progression events, in order to provide 80% power to test the null hypothesis of no difference in PFS time between treatment groups, assuming a hazard ratio (HR) of 0.8 of cetuximab + chemotherapy (CTX) over CTX alone. Significance level was fixed at 5%. The two-sided stratified log-rank test was employed, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and Karnovsky Performance Scale (KPS):&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0479</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.853</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.728</ci_lower_limit>
            <ci_upper_limit>1.000</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments</title>
        <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
        <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Time (Chinese V-Ki-ras2 Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Wild-Type Population) - Independent Review Committee (IRC) Assessments</title>
          <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
          <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.9" lower_limit="9.0" upper_limit="11.3"/>
                    <measurement group_id="O2" value="8.4" lower_limit="7.4" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified log-rank test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0012</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.696</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.558</ci_lower_limit>
            <ci_upper_limit>0.867</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</title>
        <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
        <time_frame>Time from randomisation to disease progression, death or last tumour assessment, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Progression-free Survival Time (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</title>
          <description>Duration from randomization until radiological progression (based on modified WHO criteria) or death due to any cause.
Only deaths within 60 days of last tumor assessment are considered. Patients without event are censored on the date of last tumor assessment.</description>
          <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.4" lower_limit="6.1" upper_limit="8.0"/>
                    <measurement group_id="O2" value="7.7" lower_limit="7.3" upper_limit="9.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified log-rank test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.2648</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median PFS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.171</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.887</ci_lower_limit>
            <ci_upper_limit>1.544</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time (OS)</title>
        <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
        <time_frame>Time from randomisation to death or last day known to be alive, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
        <population>ITT population (allocation to treatment groups as randomized and treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time (OS)</title>
          <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
          <population>ITT population (allocation to treatment groups as randomized and treated)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.9" lower_limit="18.5" upper_limit="21.3"/>
                    <measurement group_id="O2" value="18.6" lower_limit="16.7" upper_limit="19.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified log-rank test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0419</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.878</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.774</ci_lower_limit>
            <ci_upper_limit>0.995</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time (KRAS Wild-Type Population)</title>
        <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
        <time_frame>Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time (KRAS Wild-Type Population)</title>
          <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
          <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.5" lower_limit="21.2" upper_limit="26.3"/>
                    <measurement group_id="O2" value="20.0" lower_limit="17.4" upper_limit="21.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified log-rank test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0093</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.796</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.670</ci_lower_limit>
            <ci_upper_limit>0.946</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival Time (KRAS Mutant Population)</title>
        <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
        <time_frame>Time from randomisation to death or last day known to be alive reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 31 May 2009</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Survival Time (KRAS Mutant Population)</title>
          <description>Time from randomization to death. Patients without event are censored at the last date known to be alive or at the clinical cut-off date, whichever is later.</description>
          <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16.2" lower_limit="14.9" upper_limit="17.9"/>
                    <measurement group_id="O2" value="16.7" lower_limit="14.9" upper_limit="19.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified log-rank test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.7549</p_value>
            <method>Stratified log rank</method>
            <method_desc>Kaplan-Meier method was used to estimate median OS time. HR was calculated using Cox proportional hazards model stratified by randomization strata.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.035</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.834</ci_lower_limit>
            <ci_upper_limit>1.284</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Rate - Independent Review Committee (IRC) Assessments</title>
        <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
        <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>ITT population (allocation to treatment groups as randomized and treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Rate - Independent Review Committee (IRC) Assessments</title>
          <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
          <population>ITT population (allocation to treatment groups as randomized and treated)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46.9" lower_limit="42.9" upper_limit="51.0"/>
                    <measurement group_id="O2" value="38.7" lower_limit="34.8" upper_limit="42.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified Cochran-Mantel-Haenszel (CMH) test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.0038</p_value>
            <method>Stratified cochran-mantel haenszel test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.40</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.12</ci_lower_limit>
            <ci_upper_limit>1.77</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments</title>
        <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
        <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Rate (KRAS Wild-Type Population) - Independent Review Committee (IRC) Assessments</title>
          <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
          <population>Intent to Treat (ITT) population with KRAS Wild Type tumor status as collected until 28 August 2009</population>
          <units>percentage participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="316"/>
                <count group_id="O2" value="350"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57.3" lower_limit="51.6" upper_limit="62.8"/>
                    <measurement group_id="O2" value="39.7" lower_limit="34.6" upper_limit="45.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified Cochran-Mantel-Haenszel (CMH) test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.0001</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>2.069</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.515</ci_lower_limit>
            <ci_upper_limit>2.826</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</title>
        <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
        <time_frame>evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Best Overall Response Rate (KRAS Mutant Population) - Independent Review Committee (IRC) Assessments</title>
          <description>The best overall response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as the best overall response according to radiological assessments (based on modified WHO criteria).</description>
          <population>Intent to Treat (ITT) population with KRAS Mutant tumor status as collected until 28 August 2009</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="214"/>
                <count group_id="O2" value="183"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.3" lower_limit="25.2" upper_limit="38.0"/>
                    <measurement group_id="O2" value="36.1" lower_limit="29.1" upper_limit="43.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified Cochran-Mantel-Haenszel (CMH) test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.3475</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.822</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.544</ci_lower_limit>
            <ci_upper_limit>1.242</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Disease Control Rate - Independent Review Committee (IRC) Assessments</title>
        <description>The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).</description>
        <time_frame>Evaluations were performed every 6 weeks until progression reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>ITT population (allocation to treatment groups as randomized and treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Disease Control Rate - Independent Review Committee (IRC) Assessments</title>
          <description>The disease control rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response + Stable Disease as best overall response according to radiological assessments (based on modified WHO criteria).</description>
          <population>ITT population (allocation to treatment groups as randomized and treated)</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84.3" lower_limit="81.1" upper_limit="87.1"/>
                    <measurement group_id="O2" value="85.5" lower_limit="82.4" upper_limit="88.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The two-sided stratified Cochran-Mantel-Haenszel (CMH) test was employed at the 5% significance level, considering the randomization strata (region: Western Europe, Eastern Europe, outside Europe and KPS:&lt;80 vs. ≥80)</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.6004</p_value>
            <method>Stratified cochran-mantel haenszel test</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>0.92</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.67</ci_lower_limit>
            <ci_upper_limit>1.26</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Duration of Response - Independent Review Committee (IRC) Assessments</title>
        <description>Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).
Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.</description>
        <time_frame>Time from first assessment of complete response or partial response to disease progression, death or last tumor assessment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>ITT population (allocation to treatment groups as randomized and treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Duration of Response - Independent Review Committee (IRC) Assessments</title>
          <description>Time from first assessment of Complete Response or Partial Response to disease progression or death (within 60 days of last tumor assessment).
Patients without event are censored on the date of last tumor assessment. Tumor assessments based on modified WHO criteria.</description>
          <population>ITT population (allocation to treatment groups as randomized and treated)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.6" lower_limit="9.1" upper_limit="12.9"/>
                    <measurement group_id="O2" value="7.7" lower_limit="6.7" upper_limit="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Participants With No Residual Tumor After Metastatic Surgery</title>
        <description>Participants with no residual tumor after on-study surgery for metastases</description>
        <time_frame>time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007</time_frame>
        <population>ITT population (allocation to treatment groups as randomized and treated)</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Participants With No Residual Tumor After Metastatic Surgery</title>
          <description>Participants with no residual tumor after on-study surgery for metastases</description>
          <population>ITT population (allocation to treatment groups as randomized and treated)</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="599"/>
                <count group_id="O2" value="599"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>3.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>1.45</ci_lower_limit>
            <ci_upper_limit>6.27</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status</title>
        <description>Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
        <time_frame>at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>1125 subjects (566 Cetuximab + FOLFIRI; 559 FOLFIRI alone) completed at least 1 evaluable questionnaire &amp; were included in the Evaluable for QLQ-C30 population. Numbers at each timepoint were (Cetuximab + FOLFORI/FOLFORI alone, respectively): baseline 430/423; Week 8 421/390; Week 16 312/309; Week 24 255/244; Week 32 164/154; Week 40 122/96</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life (QOL) Assessment European Organisation for the Research and Treatment of Cancer (EORTC) QLQ-C30 Global Health Status</title>
          <description>Mean global health status scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a better QoL.</description>
          <population>1125 subjects (566 Cetuximab + FOLFIRI; 559 FOLFIRI alone) completed at least 1 evaluable questionnaire &amp; were included in the Evaluable for QLQ-C30 population. Numbers at each timepoint were (Cetuximab + FOLFORI/FOLFORI alone, respectively): baseline 430/423; Week 8 421/390; Week 16 312/309; Week 24 255/244; Week 32 164/154; Week 40 122/96</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58.88" spread="1.185"/>
                    <measurement group_id="O2" value="60.33" spread="1.155"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.02" spread="1.187"/>
                    <measurement group_id="O2" value="61.83" spread="1.176"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60.77" spread="1.276"/>
                    <measurement group_id="O2" value="63.29" spread="1.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61.83" spread="1.368"/>
                    <measurement group_id="O2" value="64.06" spread="1.364"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59.68" spread="1.590"/>
                    <measurement group_id="O2" value="65.07" spread="1.612"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63.43" spread="1.835"/>
                    <measurement group_id="O2" value="64.02" spread="1.991"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Quality of Life Assessment (EORTC QLQ-C30) Social Functioning</title>
        <description>Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.</description>
        <time_frame>at baseline, at week 8, at week 16, at week 24, at week 32, and at week 40, reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 27 July 2006</time_frame>
        <population>1125 subjects (566 in the Cetuximab + FOLFIRI arm and 559 in the FOLFIRI alone arm) completed at least one evaluable QLQ-C30 questionnaire and were thus included in the Evaluable for QLQ-C30 population</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Life Assessment (EORTC QLQ-C30) Social Functioning</title>
          <description>Mean social functioning scores (EORTC QLQ-C30) against time for each treatment group. Scores were derived from mutually exclusive sets of items, with scale scores ranging from 0 to 100 after a linear transformation. Higher scores indicate a higher level of functioning.</description>
          <population>1125 subjects (566 in the Cetuximab + FOLFIRI arm and 559 in the FOLFIRI alone arm) completed at least one evaluable QLQ-C30 questionnaire and were thus included in the Evaluable for QLQ-C30 population</population>
          <units>scores on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="566"/>
                <count group_id="O2" value="559"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>At baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="75.21" spread="1.426"/>
                    <measurement group_id="O2" value="77.28" spread="1.395"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 8</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.14" spread="1.430"/>
                    <measurement group_id="O2" value="76.71" spread="1.415"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 16</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="73.72" spread="1.533"/>
                    <measurement group_id="O2" value="76.67" spread="1.498"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 24</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.31" spread="1.644"/>
                    <measurement group_id="O2" value="77.98" spread="1.633"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 32</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.04" spread="1.903"/>
                    <measurement group_id="O2" value="75.64" spread="1.933"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>At week 40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="76.58" spread="2.198"/>
                    <measurement group_id="O2" value="78.07" spread="2.388"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety - Number of Patients Experiencing Any Adverse Event</title>
        <description>Please refer to Adverse Events section for further details</description>
        <time_frame>time from first dose up to 30 days after last dose of study treatment reported between day of first patient randomised, 10 Aug 2004, until cut-off date, 30 Nov 2007</time_frame>
        <population>Safety Population</population>
        <group_list>
          <group group_id="O1">
            <title>Cetuximab Plus FOLFIRI</title>
            <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
          <group group_id="O2">
            <title>FOLFIRI Alone</title>
            <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops</description>
          </group>
        </group_list>
        <measure>
          <title>Safety - Number of Patients Experiencing Any Adverse Event</title>
          <description>Please refer to Adverse Events section for further details</description>
          <population>Safety Population</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="600"/>
                <count group_id="O2" value="602"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="599"/>
                    <measurement group_id="O2" value="597"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from first dose up to 30 days after the last dose of study treatment.</time_frame>
      <desc>Treatment-emergent adverse events were defined as those with onset occurring at or after the first dosing day of study medication and up to 30 days after the last administration of any study drug or the clinical cut-off date.</desc>
      <group_list>
        <group group_id="E1">
          <title>Cetuximab Plus FOLFIRI</title>
          <description>Cetuximab intravenous infusion of 400mg/m^2 for the first infusion then weekly intravenous infusion of 250mg/m^2. Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops.
Safety population: includes all treated subjects.</description>
        </group>
        <group group_id="E2">
          <title>FOLFIRI Alone</title>
          <description>Bi-weekly Irinotecan infusion of 180mg/m^2, Folinic Acid infusion of 400mg/m^2 (racemic) or 200mg/m^2 (L-form), 5-Fluorouracil bolus of 400mg/m^2 followed by a 46-hour continuous infusion of 2400mg/m^2 Number of Cycles: until progression or unacceptable toxicity develops.
Safety population: includes all treated subjects</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="263" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="204" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FEBRILE BONE MARROW APLASIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="37" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PANCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PLATELET TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE CORONARY SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ARRHYTHMIA SUPRAVENTRICULAR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ARTERIOSPASM CORONARY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE CONGESTIVE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIOGENIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CARDIOPULMONARY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CONDUCTION DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PALPITATIONS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RIGHT VENTRICULAR FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACUTE CARDIO-VASCULAR INSUFFICIENCY</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CIRCULATORY INSUFFICIENCY</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>VERTIGO</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>DIABETES INSIPIDUS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACUTE ABDOMEN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ANAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ASCITES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>COLONIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="36" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSPHAGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ENTEROCOLITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ENTEROVESICAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTRIC ULCER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTRO-INTESTINAL FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HYPOMOTILITY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HAEMATEMESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HAEMATOCHEZIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ILEUS PARALYTIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INGUINAL HERNIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INTESTINAL PERFORATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MESENTERIC VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PANCREATITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PERITONEAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PERITONITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PROCTALGIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RECTAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SUBILEUS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>UPPER GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="16" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHEST PAIN</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHILLS</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DISEASE PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EXTRAVASATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GENERAL PHYSICAL HEALTH DETERIORATION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFLUENZA LIKE ILLNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFUSION SITE EXTRAVASATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFUSION SITE PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LOCALISED OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MULTI-ORGAN FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="21" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>THROMBUS//CLOT IN VEIN OF LEFT HAND CAUSING INFECTION</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>BILIARY FISTULA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHOLANGITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DILATATION INTRAHEPATIC DUCT ACQUIRED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HEPATIC FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPERBILIRUBINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>JAUNDICE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAPHYLACTIC REACTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPERSENSITIVITY</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABDOMINAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABSCESS INTESTINAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>APPENDICITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER RELATED INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CATHETER SITE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CENTRAL LINE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ERYSIPELAS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA BACTERAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ESCHERICHIA SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LISTERIOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LOWER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LUNG ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NEUTROPENIC SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>OTITIS MEDIA CHRONIC</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PELVIC ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PERIANAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PNEUMONIA KLEBSIELLA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STREPTOCOCCAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>POSTOPERATIVE WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL ABSCESS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SINUSITIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SKIN INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STAPHYLOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STREPTOCOCCAL SEPSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VARICELLA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACUTE GASTROENTERITIS</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACUTE PNEUMONIA</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INFECTION OF OSTEOSYNTHESIS IN RIGHT ANCLE</sub_title>
                <description>An organ system was assigned to this adverse event as required for posting on Clinicaltrials.gov - the organ system was not assigned in the Clinical Study Report</description>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL POISONING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ANASTOMOTIC STENOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FALL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FEMORAL NECK FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FEMUR FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FIBULA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>FRACTURED SACRUM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HIP FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INTESTINAL STOMA COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LIMB INJURY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>OVERDOSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PATELLA FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL BILE LEAK</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SPINAL COMPRESSION FRACTURE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STENT OCCLUSION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VASCULAR ACCESS COMPLICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ALANINE AMINOTRANSFERASE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>BLOOD CREATININE INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>C-REACTIVE PROTEIN INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HAEMOGLOBIN DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HEPATIC ENZYME INCREASED</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LABORATORY TEST ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NEUTROPHIL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PLATELET COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>URINE ANALYSIS ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>WHITE BLOOD CELL COUNT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CACHEXIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DIABETIC KETOACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ELECTROLYTE IMBALANCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOALBUMINAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOCALCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LACTIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MALNUTRITION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>METABOLIC ACIDOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ORAL INTAKE REDUCED</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>JOINT SWELLING</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>BLADDER NEOPLASM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CANCER PAIN</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MALIGNANT NEOPLASM PROGRESSION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>METASTASES TO CENTRAL NERVOUS SYSTEM</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>OVARIAN LOW MALIGNANT POTENTIAL TUMOUR</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>TUMOUR ASSOCIATED FEVER</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>TUMOUR HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CEREBRAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>COMA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>COORDINATION ABNORMAL</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DEPRESSED LEVEL OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EPILEPSY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LETHARGY</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LOSS OF CONSCIOUSNESS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PARAESTHESIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SOMNOLENCE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VOCAL CORD PARALYSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ABNORMAL BEHAVIOUR</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CONFUSIONAL STATE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EUPHORIC MOOD</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>CALCULUS URETERIC</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CALCULUS URINARY</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSURIA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HAEMORRHAGE URINARY TRACT</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYDRONEPHROSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NEPHROLITHIASIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RENAL COLIC</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>URETERIC OBSTRUCTION</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VAGINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>BENIGN PROSTATIC HYPERPLASIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>BRONCHOSPASM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PLEURITIC PAIN</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RESPIRATORY FAILURE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>CATARACT OPERATION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>AXILLARY VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CIRCULATORY COLLAPSE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EMBOLISM</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INTERMITTENT CLAUDICATION</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>JUGULAR VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PERIPHERAL ISCHAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PERIPHERAL OCCLUSIVE DISEASE</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SUBCLAVIAN VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VENA CAVA THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VENOUS THROMBOSIS LIMB</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 10.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="593" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="591" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>NEUTROPENIA</sub_title>
                <counts group_id="E1" subjects_affected="272" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="249" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LEUKOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="127" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="120" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="127" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="31" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>LYMPHOPENIA</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>CONJUNCTIVITIS</sub_title>
                <counts group_id="E1" subjects_affected="88" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" subjects_affected="377" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="353" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NAUSEA</sub_title>
                <counts group_id="E1" subjects_affected="322" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="359" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" subjects_affected="194" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="231" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>STOMATITIS</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="110" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" subjects_affected="142" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="154" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>CONSTIPATION</sub_title>
                <counts group_id="E1" subjects_affected="135" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="119" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSPEPSIA</sub_title>
                <counts group_id="E1" subjects_affected="78" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="46" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN UPPER</sub_title>
                <counts group_id="E1" subjects_affected="45" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>FATIGUE</sub_title>
                <counts group_id="E1" subjects_affected="192" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="186" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" subjects_affected="136" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="64" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ASTHENIA</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="112" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>MUCOSAL INFLAMMATION</sub_title>
                <counts group_id="E1" subjects_affected="82" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>OEDEMA PERIPHERAL</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="42" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>INJECTION SITE REACTION</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>PARONYCHIA</sub_title>
                <counts group_id="E1" subjects_affected="107" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NASOPHARYNGITIS</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="35" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>WEIGHT DECREASED</sub_title>
                <counts group_id="E1" subjects_affected="94" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="52" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>ANOREXIA</sub_title>
                <counts group_id="E1" subjects_affected="169" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="149" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="58" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOMAGNESAEMIA</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PAIN IN EXTREMITY</sub_title>
                <counts group_id="E1" subjects_affected="30" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>HEADACHE</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" subjects_affected="43" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="40" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSGEUSIA</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>INSOMNIA</sub_title>
                <counts group_id="E1" subjects_affected="57" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" subjects_affected="64" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="59" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DYSPNOEA</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="32" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EPISTAXIS</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>RASH</sub_title>
                <counts group_id="E1" subjects_affected="270" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ALOPECIA</sub_title>
                <counts group_id="E1" subjects_affected="224" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="229" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DERMATITIS ACNEIFORM</sub_title>
                <counts group_id="E1" subjects_affected="146" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>DRY SKIN</sub_title>
                <counts group_id="E1" subjects_affected="133" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="30" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PALMAR-PLANTAR ERYTHRODYSAESTHESIA SYNDROME</sub_title>
                <counts group_id="E1" subjects_affected="101" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="27" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SKIN FISSURES</sub_title>
                <counts group_id="E1" subjects_affected="97" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PRURITUS</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ACNE</sub_title>
                <counts group_id="E1" subjects_affected="69" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>NAIL DISORDER</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>ERYTHEMA</sub_title>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>EXFOLIATIVE RASH</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>SKIN TOXICITY</sub_title>
                <counts group_id="E1" subjects_affected="34" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>HYPERTENSION</sub_title>
                <counts group_id="E1" subjects_affected="46" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="36" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>PHLEBITIS</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="602"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="600"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="602"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <limitations_and_caveats>A non-specific outcome measure 'Safety' was deleted from the entry in error. A replacement outcome was created. The outcome refers to adverse events.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Monika Foerster/Clinical Trial Leader</name_or_title>
      <organization>Merck Serono</organization>
      <phone>+496151729517</phone>
      <email>monika.foerster@merck.de</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

